Antibody Libraries

Antibody Libraries


Specifica, a Q2 Solutions Company, develops and delivers exceptional antibody libraries to support drug discovery. Our patented Generation 3 platform yields drug-like antibodies directly from selections, minimizing the need for downstream affinity and biophysical engineering.

Specifica antibody libraries deliver:




Fast Discovery

Specifica provides high affinity antibodies with excellent developability and high diversity, saving time and money during development.


High Affinity

  • 60% of antibodies from platform have affinities below 10nM
  • 20% are in the sub-nanomolar range
  • Excluding pMHC selections, more than 75% of campaigns generate at least 1 sub-nanomolar antibody


High Diversity

  • AbXtract machine learning module groups antibodies into 10 to 1,000 distinct clusters
  • Provides antibodies against a wide variety of target epitopes with the potential for differential biology


  • Sequence liabilities are purged from all CDRs except HCDR3
  • More than 80% of antibodies have no measurable biophysical liabilities
  • Our antibodies behave as well as the best therapeutic antibodies

Related Thought Leaders Insights

CNS Biomarkers

Rules-Based Medicine, a Q2 Solutions company, offers ultrasensitive immunoassays – including beta-amyloids, GFAP, NF-L, and pTaus – for the development of diagnostics and therapeutics for Alzheimer’s...

TruCulture®: Whole blood collection and culture system for clinical studies

TruCulture from Rules-Based Medicine, a Q2 Solutions’ company, provides an innovative whole blood collection and culture system for clinical trials. TruCulture provides a standardized option that...

Multiplex Immunoassays for Idiopathic Pulmonary Fibrosis

Multiple peer-reviewed publications have consistently demonstrated a set of blood-based protein biomarkers associated with idiopathic pulmonary fibrosis (IPF) disease progression. A set of...